Vaccitech is a clinical stage T cell immunotherapy and vaccine company developing products to treat infectious diseases and cancer. The company’s proprietary platform, comprising Chimpanzee Adenovirus (prime) and MVA (boost) is designed to induce, boost and maintain CD8+ and CD4+ T cells, as well as antibodies. The Vaccitech prime-boost platform is licensed from one of the most prestigious vaccine research institutes in the world, the Jenner Institute at the University of Oxford. In partnership with the Jenner, Vaccitech co-invented and led aspects of the early development of a SARS-CoV-2 (COVID-19) vaccine, based upon its proprietary Chimpanzee Adenovirus Oxford, or ChAdOx, platform. The COVID-19 vaccine, now known as AZD1222, was assigned by Vaccitech to Oxford University Innovation and has been licensed by Oxford University Innovation to AstraZeneca.
Vaccitech has multiple therapeutic programs in the clinic including a Phase 1/2 program for chronic HBV and HPV, a Phase 2 program for prostate cancer, as well as a program preparing to enter the clinic for NSCLC. The company is also co-developing prophylactic products for MERS coronavirus and Herpes Zoster with international collaborators. Vaccitech is backed by leading institutions including GV, Sequoia Capital China, Korea Investment Partners and Oxford Sciences Innovation.